Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 874 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... December 17, 2025 Opinion: ‘UK cancer research could be set back years by COVID-19. We must act now’ June 23, 2020 Ensuring a Smooth Leadership Transition at NCI April 10, 2019 Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis,... February 10, 2026 Load more HOT NEWS EMA Recommends Extension of Indications for Idecabtagene Vicleucel NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... Are differences in treatment driving variation in ovarian cancer survival internationally? Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over...
